ARS Pharmaceuticals, Inc. Increase (Decrease) in Contract with Customer, Liability
ARS Pharmaceuticals, Inc. (SPRY) reported Increase (Decrease) in Contract with Customer, Liability of -$89.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2026-08-13
- ARS Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-06-30 was -$28.00K.
- ARS Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2026-03-31 was -$61.00K.
- ARS Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-12-31 was -$55.00K, a 102.63% decline year-over-year.
- ARS Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for the quarter ending 2025-09-30 was -$55.00K.
- ARS Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2025 was -$350.00K, a 116.75% decline from fiscal 2024.
- ARS Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2024 was $2.09M.
- ARS Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2023 was -$3.14M.
- ARS Pharmaceuticals, Inc. increase (decrease) in contract with customer, liability for fiscal 2022 was -$1.32M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 3 month | Increase (Decrease) in Contract with Customer, Liability 6 month | Increase (Decrease) in Contract with Customer, Liability 9 month | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$28.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$89.00K 10-Q · filed 2026-08-13 | -$144.00K derived: sum of 3 quarters · filed 2026-08-13 | -$199.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$61.00K 10-Q · filed 2026-05-15 | -$116.00K derived: sum of 2 quarters · filed 2026-05-15 | -$171.00K derived: sum of 3 quarters · filed 2026-05-15 | -$201.00K derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$55.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | -$110.00K derived: sum of 2 quarters · filed 2026-03-09 | -$140.00K derived: sum of 3 quarters · filed 2026-08-13 | -$350.00K 10-K · filed 2026-03-09 |
| 2025-09-30 | -$55.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$85.00K derived: sum of 2 quarters · filed 2026-08-13 | -$295.00K 10-Q · filed 2025-11-10 | $1.79M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$30.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$240.00K 10-Q · filed 2026-08-13 | $1.85M derived: sum of 3 quarters · filed 2026-08-13 | $1.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$210.00K 10-Q · filed 2026-05-15 | $1.88M derived: sum of 2 quarters · filed 2026-05-15 | $1.88M derived: sum of 3 quarters · filed 2026-05-15 | $1.88M derived: sum of 4 quarters · filed 2026-05-15 |
| 2024-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $2.09M derived: sum of 2 quarters · filed 2026-03-09 | $2.09M derived: sum of 3 quarters · filed 2026-03-09 | $2.09M 10-K · filed 2026-03-09 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $0.00 10-Q · filed 2025-11-10 | $0.00 derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $0.00 10-Q · filed 2025-08-13 | $0.00 derived: sum of 3 quarters · filed 2025-08-13 | $0.00 derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-14 | $0.00 derived: sum of 2 quarters · filed 2025-05-14 | $0.00 derived: sum of 3 quarters · filed 2025-05-14 | -$10.00K derived: sum of 4 quarters · filed 2025-05-14 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $0.00 derived: sum of 2 quarters · filed 2025-03-20 | -$10.00K derived: sum of 3 quarters · filed 2025-03-20 | -$3.14M 10-K · filed 2025-03-20 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-13 | -$10.00K derived: sum of 2 quarters · filed 2024-11-13 | -$3.14M 10-Q · filed 2024-11-13 | -$3.14M derived: sum of 4 quarters · filed 2024-11-13 |
| 2023-06-30 | -$10.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | -$3.14M 10-Q · filed 2024-08-06 | -$3.14M derived: sum of 3 quarters · filed 2024-08-06 | -$3.33M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | -$3.13M 10-Q · filed 2024-05-09 | -$3.13M derived: sum of 2 quarters · filed 2024-05-09 | -$3.32M derived: sum of 3 quarters · filed 2024-05-09 | -$3.78M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$189.00K derived: sum of 2 quarters · filed 2024-03-21 | -$653.00K derived: sum of 3 quarters · filed 2024-03-21 | -$1.32M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$189.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | -$653.00K derived: sum of 2 quarters · filed 2023-11-09 | -$1.32M 10-Q · filed 2023-11-09 | |
| 2022-06-30 | -$464.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$1.13M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | -$663.00K 10-Q · filed 2023-05-15 | |||
| 2021-12-31 | -$2.51M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| PROTHENA CORP PUBLIC LTD CO (PRTA) | Ireland | $0.428B | -11.53 |
| Turn Therapeutics Inc. (TTRX) | United States | $0.397B | -25.68 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 |